星湖科技(600866.SH)擬以募集資金向久凌製藥增資1500萬元 發展重慶研發中心建設項目
格隆匯12月2日丨星湖科技(600866.SH)公佈,公司以非公開發行股份的方式向5名特定投資者發行3807.2562萬股人民幣普通股股票(A股),募集資金總額為人民幣1.68億元,扣除各項發行費用後,實際募集資金淨額為人民幣1.58億元。
公司本次募集資金投資項目“重慶研發中心建設項目”實施主體為公司全資子公司四川久凌製藥科技有限公司(以下簡稱“久凌製藥”)。
為確保募集資金投資項目的順利實施,公司擬使用募集資金1500.00萬元向久凌製藥增資,用於募集資金投資項目建設。本次增資完畢,久凌製藥的註冊資本由803.0303萬元增至2303.0303萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.